Heliclar

Heliclar is an oral, prescription‑only medication that contains the macrolide antibiotic clarithromycin as its active ingredient. Marketed in the European Union, the product’s specific strength and dosage form are not publicly disclosed. Clarithromycin belongs to the macrolide class and works by inhibiting bacterial protein synthesis. Heliclar is used under medical supervision to treat bacterial infections that are susceptible to this antibiotic therapy effectively in clinical practice.

Heliclar, containing clarithromycin, is indicated for the treatment of a variety of bacterial infections that are known to be responsive to macrolide therapy.

- Community‑acquired pneumonia caused by susceptible Streptococcus pneumoniae and atypical pathogens. - Acute bacterial sinusitis and acute exacerbations of chronic bronchitis. - Skin and soft‑tissue infections such as cellulitis and erysipelas. - Part of combination therapy for Helicobacter pylori eradication. - Certain atypical mycobacterial infections when alternative agents are unsuitable.

Side effects of Heliclar reflect the known safety profile of clarithromycin. Common adverse events are usually mild and transient.

Common: - Nausea or upset stomach. - Diarrhea or loose stools. - Abdominal pain or cramping. - Altered taste sensation (metallic or bitter). - Headache.

Serious: - Severe allergic reactions such as anaphylaxis or rash. - QT interval prolongation leading to cardiac arrhythmias. - Hepatotoxicity manifested by jaundice or elevated liver enzymes. - Clostridioides difficile‑associated diarrhea or pseudomembranous colitis.

Before prescribing Heliclar, clinicians should evaluate several safety considerations.

- Known hypersensitivity to clarithromycin, other macrolides, or any component of the product. - Pre‑existing liver disease, as clarithromycin is metabolized hepatically. - Significant renal impairment may require dosage adjustment. - Patients with a history of QT prolongation or taking other QT‑prolonging drugs. - Concomitant use of drugs that are strong CYP3A4 substrates or inhibitors. - Pregnancy and breastfeeding status is not clearly established; use only if benefit outweighs risk.

Heliclar can affect, or be affected by, a range of other medications. Some combinations should be avoided, while others require careful monitoring.

Avoid: - Other QT‑prolonging agents (e.g., cisapride, pimozide). - Ergot alkaloids, due to risk of ergotism. - Statins metabolized by CYP3A4 such as simvastatin and lovastatin.

Use with caution: - Anticoagulants like warfarin, which may have increased INR. - Anticonvulsants (carbamazepine, phenytoin) that can reduce clarithromycin levels. - Oral contraceptives, as efficacy may be decreased. - Digoxin and colchicine, which may require dose adjustments. - Other CYP3A4 substrates, including certain calcium channel blockers.